hVEGFA&hPDL1/B16-F10
CBPG0287
询 价
留 言
产品描述
产品数据库
| I. Background | |||
| hVEGFA与hPD-L1是肿瘤微环境中两个关键的免疫抑制与促血管生成靶点，常被组合研究或设计为双特异性抑制剂。VEGFA（血管内皮生长因子A）主要驱动血管生成并抑制免疫细胞活性；PD-L1（程序性死亡配体1）则是经典的免疫检查点分子，顺利获得结合T细胞上的PD-1抑制抗肿瘤免疫应答。两者在多种肿瘤中表达常呈正相关，联合阻断在部分癌种（如肾细胞癌、非小细胞肺癌）中已显示出协同疗效。 | |||
| II. Introduction | |||
| Host Cell: | B16-F10 | ||
| Expressed gene: | hVEGFA&hPDL1 | ||
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) | ||
| Freeze Medium: | 90% FBS+10% DMSO | ||
| Culture Medium: | DMEM + 10% FBS + 2 μg/ml Puromycin + 5 μg/ml Blasticidin | ||
| Mycoplasma Testing: | Negative | ||
| Storage: | Liquid nitrogen | ||
| III. Description of Host Cell Line | |||
| Organism: | Mus musculus, mouse | ||
| Tissue: | Skin | ||
| Morphology: | Mixture of spindle-shaped and epithelial-like cells | ||
| Growth Properties: | Adherent | ||
| IV. Representative Data | |||
|
Figure 1. Recombinant hVEGFA&hPDL1/B16-F10 stably expressing hPDL1. |
|||
